April 27, 2020 / 11:51 AM / a month ago

BRIEF-Kamada And Kedrion Biopharma Announce Global Collaboration For The Development, Manufacturing And Distribution Of A Plasma-Derived Anti-Sars-Cov-2 (Covid-19) Polyclonal Immunoglobulin Product

April 27 (Reuters) - Kamada Ltd:

* KAMADA AND KEDRION BIOPHARMA ANNOUNCE GLOBAL COLLABORATION FOR THE DEVELOPMENT, MANUFACTURING AND DISTRIBUTION OF A PLASMA-DERIVED ANTI-SARS-COV-2 (COVID-19) POLYCLONAL IMMUNOGLOBULIN PRODUCT

* KAMADA- RESPONSIBLE FOR PRODUCT DEV, MANUFACTURING, CLINICAL DEVELOPMENT, REGULATORY SUBMISSIONS, DISTRIBUTION IN TERRITORIES NOT UNDER KEDRION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below